Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,705,863
  • Shares Outstanding, K 165,118
  • Annual Sales, $ 1,558 M
  • Annual Income, $ 367,070 K
  • EBIT $ 359 M
  • EBITDA $ 387 M
  • 60-Month Beta 0.49
  • Price/Sales 3.09
  • Price/Cash Flow 11.00
  • Price/Book 2.78

Options Overview Details

View History
  • Implied Volatility 54.49% (+8.50%)
  • Historical Volatility 40.32%
  • IV Percentile 60%
  • IV Rank 24.26%
  • IV High 112.83% on 07/17/25
  • IV Low 35.80% on 03/17/25
  • Expected Move (DTE 6) 1.26 (4.41%)
  • Put/Call Vol Ratio 8.99
  • Today's Volume 2,928
  • Volume Avg (30-Day) 493
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 11,102
  • Open Int (30-Day) 14,808
  • Expected Range 27.24 to 29.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.35
  • Number of Estimates 2
  • High Estimate 0.39
  • Low Estimate 0.31
  • Prior Year 0.92
  • Growth Rate Est. (year over year) -61.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.81 +2.50%
on 12/10/25
31.74 -10.19%
on 11/13/25
-2.91 (-9.25%)
since 11/12/25
3-Month
26.40 +7.95%
on 09/15/25
36.32 -21.53%
on 11/05/25
+1.53 (+5.67%)
since 09/12/25
52-Week
25.17 +13.25%
on 09/08/25
36.45 -21.81%
on 02/18/25
-2.00 (-6.56%)
since 12/12/24

Most Recent Stories

More News
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL

NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating...

AVDL : 21.36 (-0.14%)
ALKS : 28.50 (-2.30%)
Announcement relating to despatch of Rule 15 proposal

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....

AVDL : 21.36 (-0.14%)
ALKS : 28.50 (-2.30%)
Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 8 th Annual Evercore Healthcare...

ALKS : 28.50 (-2.30%)
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...

AVDL : 21.36 (-0.14%)
ALKS : 28.50 (-2.30%)
Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR...

AVDL : 21.36 (-0.14%)
ALKS : 28.50 (-2.30%)
Alkermes Response to Avadel Announcement

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS...

ALKS : 28.50 (-2.30%)
Avadel Receives Unsolicited Proposal from Lundbeck

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR...

AVDL : 21.36 (-0.14%)
ALKS : 28.50 (-2.30%)
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 –

ALKS : 28.50 (-2.30%)
Alkermes to Participate in Two Upcoming Investor Conferences

DUBLIN , Nov. 6, 2025 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.

ALKS : 28.50 (-2.30%)
FORM 8.1(a) & (b) (Opening Position Disclosure)

DUBLIN , Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS):

ALKS : 28.50 (-2.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major...

See More

Key Turning Points

3rd Resistance Point 30.02
2nd Resistance Point 29.69
1st Resistance Point 29.09
Last Price 28.50
1st Support Level 28.16
2nd Support Level 27.83
3rd Support Level 27.23

See More

52-Week High 36.45
Fibonacci 61.8% 32.14
Fibonacci 50% 30.81
Fibonacci 38.2% 29.48
Last Price 28.50
52-Week Low 25.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar